54.37
price down icon3.07%   -1.72
after-market After Hours: 54.35 -0.02 -0.04%
loading
Novo Nordisk Adr stock is traded at $54.37, with a volume of 14.63M. It is down -3.07% in the last 24 hours and down -6.58% over the past month. With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$56.09
Open:
$53.88
24h Volume:
14.63M
Relative Volume:
0.83
Market Cap:
$184.32B
Revenue:
$45.45B
Net Income/Loss:
$16.18B
P/E Ratio:
14.98
EPS:
3.6297
Net Cash Flow:
$8.96B
1W Performance:
-4.50%
1M Performance:
-6.58%
6M Performance:
-6.39%
1Y Performance:
-54.01%
1-Day Range:
Value
$53.54
$54.44
1-Week Range:
Value
$53.54
$58.12
52-Week Range:
Value
$45.05
$118.27

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Name
Novo Nordisk Adr
Name
Phone
-
Name
Address
-
Name
Employee
78,387
Name
Twitter
@novonordisk
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
54.37 249.23B 45.45B 16.18B 8.96B 3.6297
Drug Manufacturers - General icon
LLY
Lilly Eli Co
802.83 734.54B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
193.22 462.69B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
229.57 400.78B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
131.43 253.15B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.79 209.61B 63.43B 16.42B 14.72B 6.4861

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-01-25 Upgrade HSBC Securities Hold → Buy
Sep-29-25 Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-17-25 Upgrade Berenberg Hold → Buy
Sep-16-25 Upgrade Rothschild & Co Redburn Neutral → Buy
Sep-09-25 Upgrade Bernstein Mkt Perform → Outperform
Aug-13-25 Upgrade BNP Paribas Exane Underperform → Neutral
Aug-05-25 Downgrade UBS Buy → Neutral
Jul-31-25 Downgrade HSBC Securities Buy → Hold
Jul-30-25 Downgrade Barclays Overweight → Equal Weight
Apr-17-25 Downgrade BMO Capital Markets Outperform → Market Perform
Mar-13-25 Upgrade Kepler Hold → Buy
Mar-03-25 Downgrade Stifel Buy → Hold
Feb-12-25 Initiated Morgan Stanley Equal-Weight
Jan-06-25 Upgrade Bernstein Underperform → Mkt Perform
May-30-24 Initiated Goldman Buy
Apr-12-24 Initiated BMO Capital Markets Outperform
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Neutral
Dec-01-23 Initiated Cantor Fitzgerald Overweight
Oct-02-23 Initiated Argus Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-15-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22 Downgrade UBS Neutral → Sell
Jun-27-22 Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22 Upgrade JP Morgan Neutral → Overweight
May-31-22 Upgrade Guggenheim Neutral → Buy
Apr-25-22 Upgrade Cowen Market Perform → Outperform
Apr-12-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22 Upgrade Deutsche Bank Hold → Buy
Jan-25-22 Downgrade Liberum Hold → Sell
Dec-20-21 Downgrade JP Morgan Overweight → Neutral
Dec-17-21 Downgrade Deutsche Bank Buy → Hold
Jan-20-21 Downgrade Credit Suisse Outperform → Neutral
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Hold
Jul-06-20 Downgrade BofA Securities Buy → Neutral
May-11-20 Downgrade UBS Buy → Neutral
May-04-20 Initiated Cowen Market Perform
Mar-16-20 Upgrade BofA/Merrill Neutral → Buy
Jan-03-20 Downgrade Guggenheim Buy → Neutral
Nov-18-19 Upgrade Barclays Equal Weight → Overweight
Sep-17-19 Upgrade Citigroup Neutral → Buy
Aug-30-19 Downgrade Jefferies Hold → Underperform
Jun-20-19 Downgrade Deutsche Bank Buy → Hold
Jun-11-19 Upgrade Barclays Underweight → Equal Weight
Apr-29-19 Upgrade Credit Suisse Neutral → Outperform
Jan-29-19 Initiated Exane BNP Paribas Outperform
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Dec-29-17 Upgrade JP Morgan Underweight → Neutral
Dec-06-17 Upgrade BofA/Merrill Neutral → Buy
Dec-01-17 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17 Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17 Upgrade BofA/Merrill Underperform → Neutral
View All

Novo Nordisk Adr Stock (NVO) Latest News

pulisher
Oct 16, 2025

Novo Nordisk Stock Seen Undervalued Despite Pullback and 2026 Growth Focus - Investing.com

Oct 16, 2025
pulisher
Oct 11, 2025

Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm

Oct 11, 2025
pulisher
Oct 11, 2025

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 10, 2025

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Oct 10, 2025
pulisher
Oct 09, 2025

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm

Oct 09, 2025
pulisher
Oct 02, 2025

BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail

Oct 02, 2025
pulisher
Oct 01, 2025

J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 01, 2025
pulisher
Sep 30, 2025

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 30, 2025
pulisher
Sep 28, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa

Sep 28, 2025
pulisher
Sep 27, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India

Sep 27, 2025
pulisher
Sep 26, 2025

Novo Nordisk A/S Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your RightsNVO - Sahm

Sep 26, 2025
pulisher
Sep 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent

Sep 24, 2025
pulisher
Sep 24, 2025

NVO Stock Quote Price and Forecast - CNN

Sep 24, 2025
pulisher
Sep 23, 2025

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 23, 2025
pulisher
Sep 20, 2025

NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 20, 2025
pulisher
Sep 19, 2025

Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com

Sep 19, 2025
pulisher
Sep 18, 2025

Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize

Sep 18, 2025
pulisher
Sep 18, 2025

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm

Sep 18, 2025
pulisher
Sep 18, 2025

Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com

Sep 18, 2025
pulisher
Sep 18, 2025

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study - Sahm

Sep 18, 2025
pulisher
Sep 17, 2025

How Do Investors Really Feel About Novo Nordisk? - Sahm

Sep 17, 2025
pulisher
Sep 17, 2025

NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 17, 2025
pulisher
Sep 17, 2025

Live market analysis of Novo Nordisk A s (b Shares) AdrhedgedInsider Buying & Comprehensive Market Scan Insights - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

Published on: 2025-09-17 04:52:55 - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

Advanced analytics toolkit walkthrough for Novo Nordisk A s (b Shares) AdrhedgedGap Down & AI Powered Trade Plan Recommendations - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit - Sahm

Sep 17, 2025
pulisher
Sep 16, 2025

Eugenio Catone @CatoneEugenio: "Great news for our second..." - eToro

Sep 16, 2025

Novo Nordisk Adr Stock (NVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$298.81
price up icon 1.01%
drug_manufacturers_general MRK
$84.79
price up icon 1.04%
$122.84
price up icon 4.23%
drug_manufacturers_general PFE
$24.51
price up icon 1.16%
drug_manufacturers_general SNY
$50.62
price up icon 1.20%
Cap:     |  Volume (24h):